2016
DOI: 10.1016/j.ejmech.2016.07.018
|View full text |Cite
|
Sign up to set email alerts
|

In vitro and in vivo studies of the antineoplastic activity of copper (II) compounds against human leukemia THP-1 and murine melanoma B16-F10 cell lines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
16
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 41 publications
(19 citation statements)
references
References 70 publications
1
16
0
Order By: Relevance
“…Therefore, complex 1 was selected for further studies. Additionally, when compared to other Cu II complexes containing analogous ligands, complex 1 has already been shown to stand out as one of the most active copper-based compounds 25 , 26 with high selectivity 22 , as it can be confirmed by the present work.…”
Section: Discussionsupporting
confidence: 80%
“…Therefore, complex 1 was selected for further studies. Additionally, when compared to other Cu II complexes containing analogous ligands, complex 1 has already been shown to stand out as one of the most active copper-based compounds 25 , 26 with high selectivity 22 , as it can be confirmed by the present work.…”
Section: Discussionsupporting
confidence: 80%
“…For B16 cells, when treated with (2), the cell viability decreased to 5%, with IC 50 values of 6.88 µg/mL (7.6 µM) after 24 h treatment and 4.15 µg/mL (4.58 µM) after 48 h, respectively (Table 3). The ligand dmtp did not affect the viability of either BJ or B16 cells at 24 or 48 h. It is worth mentioning that for other copper compounds tested on melanoma cells, the reported IC 50 values were similar [35][36][37][38][39][40][41][42][43], and only one study reported lower values [38] compared with those found for complex (1).…”
Section: Biological Characterization 231 Cell Viability and Lactate Dehydrogenase Assaysmentioning
confidence: 95%
“…The Cu(II) systems represent beneficial species from this point of view, considering their reduced systemic toxicity [16]. Thus, several Cu(II) complexes were studied and proved to be as effective for melanoma treatment [18,29,[35][36][37][38][39][40][41][42][43]-some having, in addition, low toxicity on normal cells [18,29,[39][40][41][42][43].…”
Section: Biological Characterization 231 Cell Viability and Lactate Dehydrogenase Assaysmentioning
confidence: 99%
“…Current research focuses on the design and synthesis of new complex metal antitumor agents with better biological activity and selectivity, reduced toxicity, and mechanisms of action other than those of platinum compounds, capable of overcoming the unresolved clinical problems of analogue drugs of cisplatin (serious side effects, general toxicity, and resistance) [ 5 , 6 ]. In this context, Cu +2 complexes present encouraging prospects [ 7 , 8 , 9 , 10 , 11 ].…”
Section: Introductionmentioning
confidence: 99%